• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Promises and challenges of adoptive T-cell therapies for solid tumours

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    33782566.pdf
    Size:
    1.759Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Morotti, M.
    Albukhari, A.
    Alsaadi, A.
    Artibani, M.
    Brenton, J. D.
    Curbishley, S. M.
    Dong, T.
    Dustin, M. L.
    Hu, Z.
    McGranahan, N.
    Miller, M. L.
    Santana-Gonzalez, L.
    Seymour, L. W.
    Shi, T.
    Van Loo, P.
    Yau, C.
    White, H.
    Wietek, N.
    Church, D. N.
    Wedge, David C
    Ahmed, A. A.
    Show allShow less
    Affiliation
    Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Cancer is a leading cause of death worldwide and, despite new targeted therapies and immunotherapies, many patients with advanced-stage- or high-risk cancers still die, owing to metastatic disease. Adoptive T-cell therapy, involving the autologous or allogeneic transplant of tumour-infiltrating lymphocytes or genetically modified T cells expressing novel T-cell receptors or chimeric antigen receptors, has shown promise in the treatment of cancer patients, leading to durable responses and, in some cases, cure. Technological advances in genomics, computational biology, immunology and cell manufacturing have brought the aspiration of individualised therapies for cancer patients closer to reality. This new era of cell-based individualised therapeutics challenges the traditional standards of therapeutic interventions and provides opportunities for a paradigm shift in our approach to cancer therapy. Invited speakers at a 2020 symposium discussed three areas-cancer genomics, cancer immunology and cell-therapy manufacturing-that are essential to the effective translation of T-cell therapies in the treatment of solid malignancies. Key advances have been made in understanding genetic intratumour heterogeneity, and strategies to accurately identify neoantigens, overcome T-cell exhaustion and circumvent tumour immunosuppression after cell-therapy infusion are being developed. Advances are being made in cell-manufacturing approaches that have the potential to establish cell-therapies as credible therapeutic options. T-cell therapies face many challenges but hold great promise for improving clinical outcomes for patients with solid tumours.
    Citation
    Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021.
    Journal
    British Journal of Cancer
    URI
    http://hdl.handle.net/10541/623942
    DOI
    10.1038/s41416-021-01353-6
    PubMed ID
    33782566
    Additional Links
    https://dx.doi.org/10.1038/s41416-021-01353-6
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1038/s41416-021-01353-6
    Scopus Count
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    • Authors: Zhang E, Gu J, Xu H
    • Issue date: 2018 Jan 12
    • An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    • Authors: Ott PA, Dotti G, Yee C, Goff SL
    • Issue date: 2019 Jan
    • Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    • Authors: Kosti P, Maher J, Arnold JN
    • Issue date: 2018
    • CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges.
    • Authors: Bagley SJ, Desai AS, Linette GP, June CH, O'Rourke DM
    • Issue date: 2018 Oct 9
    • CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
    • Authors: Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM
    • Issue date: 2018
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.